Venetoclax in Combination with LDAC in Treatment-Naive Japanese AML Subjects in Expanded Access Study [M19-916]

An Expanded Access Study for Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naive Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction Therapy in Japan [M19-916]

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080225347

Enrollment

Registered

2020-08-25

Start date

2020-09-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

investigational material(s) Generic name etc : INN of investigational material : venetoclax Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational materi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
safety	—

Countries

Japan

Outcome results